Clinical trials in Badalona – page 12

768 clinical trials in Badalona, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Badalona at a glance

768

clinical trials

Research sites3

Quick filters

768 trials in Badalona

Open in trial search

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Colorectal cancer

Recruiting

Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

Registered drugNo placebo

Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Ono Pharmaceutical Co. Ltd.

Contact Research Centre

COVID-19

Recruiting

Study of Remdesivir to Prevent Severe COVID-19 in Kidney Transplant Recipients with No or Mild Symptoms

Registered drugNo placebo

Study of Remdesivir to Prevent Severe COVID-19 in Kidney Transplant Recipients with No or Mild Symptoms

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Remdesivir
Sponsor:Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia

Contact Research Centre

Dermatitis atopic

Recruiting

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pimecrolimus
Sponsor:Novartis Pharma AG

Contact Research Centre

Rhinitis allergic+1

Recruiting

Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

Investigational

Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

Investigational

Spain

Participants:0–17 years · 18–64 years
Substances:Sodium Chloride
Sponsor:Advanced Outcomes Research S.L.

Contact Research Centre

Atrial fibrillation+1

Recruiting

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Flecainide Acetate
Sponsor:University Medical Center Hamburg-Eppendorf

Contact Research Centre

Non-small cell lung cancer

Recruiting

Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

Registered drugNo placebo

Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Fundacion GECP

Contact Research Centre

Colorectal cancer

Recruiting

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Fondazione GONO G.I.

Contact Research Centre

HER2 positive breast cancer

Recruiting

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Contact Research Centre

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Hormone receptor positive breast cancer+1

Recruiting

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Badalona

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for multiple types of cancer such as pancreatic, gastric, and lung cancer. Research emphasizes novel therapeutic approaches and combination treatments.

Mantle Cell Lymphoma Studies
Advanced NSCLC Treatments
Breast Cancer Therapies

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Research focusing on inflammatory and autoimmune disorders, with particular emphasis on new therapeutic approaches for various conditions affecting different body systems.

Cutaneous Lupus Erythematosus
Plaque Psoriasis
Hidradenitis Suppurativa

Trials aim to evaluate novel treatments and improve disease management strategies.

03 Infectious Diseases

Comprehensive studies addressing viral infections and preventive measures, including vaccine development and therapeutic interventions for various infectious diseases.

COVID-19 Vaccines
HIV Treatment
RSV Prevention

Focus on developing effective treatments and preventive strategies for viral infections.

Back to Spain All countries